Editas Medicine, Inc. (EDIT): Price and Financial Metrics

Editas Medicine, Inc. (EDIT): $7.30

-0.75 (-9.32%)

POWR Rating

Component Grades













Add EDIT to Watchlist
Sign Up

Industry: Biotech



in industry


  • EDIT scores best on the Value dimension, with a Value rank ahead of 54.77% of US stocks.
  • EDIT's strongest trending metric is Growth; it's been moving down over the last 179 days.
  • EDIT's current lowest rank is in the Sentiment metric (where it is better than 0.37% of US stocks).

EDIT Stock Summary

  • EDITAS MEDICINE INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 11.7% of US listed stocks.
  • With a price/sales ratio of 25.54, EDITAS MEDICINE INC has a higher such ratio than 94.97% of stocks in our set.
  • As for revenue growth, note that EDIT's revenue has grown -22.83% over the past 12 months; that beats the revenue growth of only 8.38% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to EDITAS MEDICINE INC, a group of peers worth examining would be RARE, CYCN, FIXX, SLDB, and FDMT.
  • EDIT's SEC filings can be seen here. And to visit EDITAS MEDICINE INC's official web site, go to www.editasmedicine.com.

EDIT Valuation Summary

  • EDIT's price/sales ratio is 29.3; this is 1442.11% higher than that of the median Healthcare stock.
  • Over the past 87 months, EDIT's price/sales ratio has gone down 369.5.

Below are key valuation metrics over time for EDIT.

Stock Date P/S P/B P/E EV/EBIT
EDIT 2023-03-17 29.3 1.6 -2.6 -2.1
EDIT 2023-03-16 29.7 1.6 -2.7 -2.2
EDIT 2023-03-15 29.5 1.6 -2.6 -2.2
EDIT 2023-03-14 29.5 1.6 -2.6 -2.2
EDIT 2023-03-13 29.5 1.6 -2.6 -2.2
EDIT 2023-03-10 27.4 1.5 -2.4 -2.0

EDIT Growth Metrics

    The 2 year revenue growth rate now stands at 6.74%.
  • Its year over year revenue growth rate is now at -71.79%.
  • Its year over year cash and equivalents growth rate is now at -40.58%.
EDIT's revenue has moved up $5,113,000 over the prior 33 months.

The table below shows EDIT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 25.644 -169.658 -201.13
2022-06-30 31.799 -162.439 -184.486
2022-03-31 25.816 -163.551 -186.289
2021-12-31 25.544 -163.803 -192.502
2021-09-30 24.494 -169.321 -213.565
2021-06-30 81.138 -183.337 -166.664

EDIT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EDIT has a Quality Grade of D, ranking ahead of 12.21% of graded US stocks.
  • EDIT's asset turnover comes in at 0.12 -- ranking 248th of 682 Pharmaceutical Products stocks.
  • SMMT, SAGE, and VSTM are the stocks whose asset turnover ratios are most correlated with EDIT.

The table below shows EDIT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.120 1 -0.458
2021-03-31 0.140 1 -0.450
2020-12-31 0.158 1 -0.468
2020-09-30 0.164 1 -0.447
2020-06-30 0.065 1 -0.704
2020-03-31 0.057 1 -0.806

EDIT Price Target

For more insight on analysts targets of EDIT, see our EDIT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $50.75 Average Broker Recommendation 1.79 (Moderate Buy)

EDIT Stock Price Chart Interactive Chart >

Price chart for EDIT

EDIT Price/Volume Stats

Current price $7.30 52-week high $21.59
Prev. close $8.05 52-week low $7.27
Day low $7.27 Volume 1,917,500
Day high $8.03 Avg. volume 1,759,544
50-day MA $9.13 Dividend yield N/A
200-day MA $12.01 Market Cap 503.48M

Editas Medicine, Inc. (EDIT) Company Bio

Editas Medicine Inc. operates as a genome editing company. It focuses on translating its genome editing technology into a class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a range of diseases at the genetic level. Editas Medicine Inc. was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. The company was founded in 2013 and is based in Cambridge, Massachusetts.

EDIT Latest News Stream

Event/Time News Detail
Loading, please wait...

EDIT Latest Social Stream

Loading social stream, please wait...

View Full EDIT Social Stream

Latest EDIT News From Around the Web

Below are the latest news stories about EDITAS MEDICINE INC that investors may wish to consider to help them evaluate EDIT as an investment opportunity.

US Government Assures Fund Accessibility to SVB (SIVB) Clients

Following the collapse of Silicon Valley Bank (SIVB), the go-to bank for US tech startups, U.S. banking regulators step in to assure access to funds to the bank's customers, especially startups.

Yahoo | March 13, 2023

Editas Medicine Strengthens Executive Leadership Team with Appointment of Linea Aspesi as Chief People Officer

Linea Aspesi Linea Aspesi, Executive Vice President and Chief People Officer, Editas Medicine CAMBRIDGE, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Linea Aspesi as the Company’s Executive Vice President and Chief People Officer. Ms. Aspesi will lead Editas’ human resources department and the Company’s people strategy in support of its mission and goals. “Our people and our culture are

Yahoo | March 8, 2023

Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2022 Earnings Call Transcript

Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2022 Earnings Call Transcript February 22, 2023 Operator: Good morning and welcome to Editas Medicine’s Fourth Quarter and Full-year 2022 Conference Call. All participants are now in a listen-only mode. There will be a question-and-answer session at the end of this call. Please be advised that this call is being […]

Yahoo | February 23, 2023

Editas (EDIT) Q4 Earnings Miss Estimates, Pipeline in Focus

Editas (EDIT) reports a wider loss in the fourth quarter of 2022. The strategic reprioritization, announced last month, is expected to extend the company's cash runway into 2025.

Yahoo | February 23, 2023

Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates

Editas (EDIT) delivered earnings and revenue surprises of -4.76% and 43.33%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 22, 2023

Read More 'EDIT' Stories Here

EDIT Price Returns

1-mo -20.48%
3-mo -17.42%
6-mo -42.61%
1-year -59.91%
3-year -62.72%
5-year -80.74%
YTD -17.70%
2022 -66.59%
2021 -62.13%
2020 136.78%
2019 30.15%
2018 -25.97%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8464 seconds.